![IL-1 α and -1β induce TTP in ADAMTS13KO mice. (A) Platelet levels at 10 hours in ADAMTS13 KO mice (KO) or WT mice injected with IL-1α, IL-1β, or PBS (n = 5 per group). Two-way ANOVA for genotype: P < .001 and for injected compound: P < .001. Platelet levels in KO/IL-1α: 205 (140-271) × 109/L; KO/IL-1β: 189 (166-246) × 109/L; and KO/PBS: 763 (700-995) × 109/L. (B) VWF levels between 0 hours and 10 hours in ADAMTS13 KO mice or WT mice injected with IL-1α, IL-1β, or PBS (n = 5 per group). VWF levels in KO/IL-1α: 3040 (270-4610) %; KO/IL-1β: 3050 (1500-8670) %; and KO/PBS: 120 (60-130) ng/mL. VWF levels in WT/IL-1α: 180 (160-220) ng/mL; WT/IL-1β: 170 (140-180) ng/mL; and WT/PBS: 70 (50-80) ng/mL. (C) Blood troponin I levels between 0 hours and 10 hours in ADAMTS13 KO mice or WT mice injected with Ilα, IL-1β, or PBS (n = 5 per group). Two-way ANOVA for genotype: P < .001; and for injected compound: P < .001. Troponin I levels in KO/IL-1α: 4.7 (4.0-5.3) ng/mL; KO/IL-1β: 5. 9(3.5-8.9) ng/mL; and KO/PBS: 0.7 (0.4-0.9) ng/mL. (D) Semiquantitative assessment of myocardial damage. Two-way ANOVA for genotype: P < .001; and injected compound: P = .008. Scores in KO/IL-1α: 5.0 (2.3-6.4); KO/IL-1β: 3.8 (2.5-5.3); and KO/PBS: 1.7 (2.5-7.3). (E) Immunofluorescence measurement of intravascular VWF; green, anti-VWF antibodies; blue, DAPI [4’,6-diamidino-2-phenylindole]). Two-way ANOVA for genotype: P < .001; and injected compound: P = .005. Capillary fluorescence: KO/IL-1α: 2,6 (2,5-2,8) × 106 UA vs KO/IL-1β: 2,7 (2,5-2,9) × 106 UA and KO/PBS: 2,0 (1,8-2,2) × 106 UA (ns: P > .05; ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001). UA (arbitrary unit).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/143/26/10.1182_blood.2023021974/3/blood_bld-2023-021974-gr6.jpeg?Expires=1754060971&Signature=qIfUGLMT49qaj9R52t~H9-ofBD~lpaxdL7cdI-vek-IrGUZ0Ag04ZncSUFi9esEoscsfN2dK4UuhdrCvg7eeJTKODFzyisu1unB8~w47XFFqTAybvWSR8RPTaDPji2tp73nulmxPhBQU4YvQ8D8Zdfm2UJKS8-ZZNiolzGSWNqTWwBxZHtYQwOj4BYnWUUfZp3pV8Y-d1unJ2lns6WXmpLdRhkh04rx0nHR2W~B7vhbayGsJhqHKlcLqOD0DOMzlKDj6B66it9SMyIzRp07PgmmaixmMn1KB6Mqnvfd77mkaqI~BGXeuUF5kxMrld~5H0jPMDO9w14PeUQ6yjL4kMA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
IL-1 α and -1β induce TTP in ADAMTS13KO mice. (A) Platelet levels at 10 hours in ADAMTS13 KO mice (KO) or WT mice injected with IL-1α, IL-1β, or PBS (n = 5 per group). Two-way ANOVA for genotype: P < .001 and for injected compound: P < .001. Platelet levels in KO/IL-1α: 205 (140-271) × 109/L; KO/IL-1β: 189 (166-246) × 109/L; and KO/PBS: 763 (700-995) × 109/L. (B) VWF levels between 0 hours and 10 hours in ADAMTS13 KO mice or WT mice injected with IL-1α, IL-1β, or PBS (n = 5 per group). VWF levels in KO/IL-1α: 3040 (270-4610) %; KO/IL-1β: 3050 (1500-8670) %; and KO/PBS: 120 (60-130) ng/mL. VWF levels in WT/IL-1α: 180 (160-220) ng/mL; WT/IL-1β: 170 (140-180) ng/mL; and WT/PBS: 70 (50-80) ng/mL. (C) Blood troponin I levels between 0 hours and 10 hours in ADAMTS13 KO mice or WT mice injected with Ilα, IL-1β, or PBS (n = 5 per group). Two-way ANOVA for genotype: P < .001; and for injected compound: P < .001. Troponin I levels in KO/IL-1α: 4.7 (4.0-5.3) ng/mL; KO/IL-1β: 5. 9(3.5-8.9) ng/mL; and KO/PBS: 0.7 (0.4-0.9) ng/mL. (D) Semiquantitative assessment of myocardial damage. Two-way ANOVA for genotype: P < .001; and injected compound: P = .008. Scores in KO/IL-1α: 5.0 (2.3-6.4); KO/IL-1β: 3.8 (2.5-5.3); and KO/PBS: 1.7 (2.5-7.3). (E) Immunofluorescence measurement of intravascular VWF; green, anti-VWF antibodies; blue, DAPI [4’,6-diamidino-2-phenylindole]). Two-way ANOVA for genotype: P < .001; and injected compound: P = .005. Capillary fluorescence: KO/IL-1α: 2,6 (2,5-2,8) × 106 UA vs KO/IL-1β: 2,7 (2,5-2,9) × 106 UA and KO/PBS: 2,0 (1,8-2,2) × 106 UA (ns: P > .05; ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001). UA (arbitrary unit).
